You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
萬泰生物(603392.SH):面對新廠家HPV疫苗的陸續上市,公司二價HPV疫苗的國內市場確實承受了不小的壓力
格隆匯 07-16 16:50

格隆匯7月16日丨萬泰生物(603392.SH)在互動平台表示,面對新廠家HPV疫苗的陸續上市,公司二價HPV疫苗的國內市場確實承受了不小的壓力。但從市場潛力分析,9-45歲適齡女性仍有很高的存量市場,公司二價HPV疫苗作為目前國產唯一獲得WHO PQ認證的宮頸癌疫苗,在其經濟價值、產品質量等方面有特定人羣優勢。 產品方面,公司擁有自主知識產權的大腸桿菌原核表達類病毒顆粒疫苗技術體系,該技術具有安全性高、生產成本低、表達速度高、生產工藝簡單等特點。基於此技術平台上市的二價HPV疫苗不管是預防HPV16型、18型所導致病變的效果還是預防HPV16型、18型的持續感染都有一定優勢;同時具備產能大、提升快、成本低的優勢。 市場方面,公司在保障國內市場供應的同時,積極開拓國際市場,已獲得十餘個國家的上市許可,今年將圍繞全球尚未將HPV疫苗納入國家計劃免疫規劃的國家開展市場拓展和銷售工作。公司根據競爭環境調整市場策略,走差異化優勢,鞏固市場佔有率。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account